Management of hypotension
"hypotension" AND "management"
| Type | Mechanism | Examples |
|---|---|---|
| Hypovolemic | Reduced preload / volume loss | Hemorrhage, dehydration, burns |
| Distributive | Vasodilation / maldistribution | Sepsis, anaphylaxis, neurogenic, drug-induced |
| Cardiogenic | Pump failure | MI, arrhythmia, myocarditis, valvular disease |
| Obstructive | Outflow obstruction | PE, tension pneumothorax, cardiac tamponade |
"Vasopressors are typically initiated when hemodynamic stability cannot be restored with fluid administration alone." - Miller's Anesthesia, 10e
| Drug | Mechanism | Use | Notes |
|---|---|---|---|
| Vasopressin | V1 receptor - direct vasoconstriction; no inotropic/chronotropic effect | Add-on to norepinephrine in septic shock (up to 0.03 units/min) | Raises MAP or allows norepinephrine dose reduction; not recommended as sole initial vasopressor |
| Epinephrine | α + β1 + β2 stimulation | Second agent in septic shock when norepinephrine insufficient; first-line for anaphylaxis | Risk of arrhythmias and lactic acidosis |
| Phenylephrine | Selective α1 agonist | Hypotension in non-septic contexts; spinal anesthesia-related hypotension | Reflex bradycardia and reduced CO; not recommended in septic shock |
| Dopamine | Dose-dependent DA, β1, α receptor activation | No longer recommended as first-line for septic shock; associated with more arrhythmias | Indirect-acting; inferior to norepinephrine in most trials |
| Dobutamine | β1 > β2 agonist (inotrope) | Cardiogenic shock - augments contractility | Not a vasopressor; may worsen hypotension via vasodilation if used alone |

| Drug | Dose | Key Notes |
|---|---|---|
| Fludrocortisone | 0.1-0.2 mg oral daily | Volume expander; risk of supine hypertension and hypokalemia |
| Midodrine (α1 agonist) | 5-10 mg oral TID | Take before rising; no later than 3-4 hrs before bedtime |
| Droxidopa (norepinephrine precursor) | 100-600 mg oral TID | Same timing as midodrine; avoid supine use |
| Pyridostigmine | 30-60 mg TID | Useful when supine hypertension limits fludrocortisone/midodrine |
| Atomoxetine | 10-18 mg BID | Better for patients with preserved sympathetic terminals |
| Acarbose / Octreotide | Various | Adjuvant for postprandial hypotension |
| Erythropoietin | 25-75 U/kg SQ TIW | For anemia-driven worsening; requires iron supplementation |
| Parameter | Target |
|---|---|
| MAP | ≥65 mmHg (or higher in chronic hypertensives) |
| Urine output | ≥0.5 mL/kg/hr |
| Lactate | Trend to normalization (<2 mmol/L) |
| ScvO2 | >70% (if measured) |
Recent systematic review: Intraoperative hypotension management strategies (Lee et al., Anesth Analg 2025, PMID 38870081) confirms individualized blood pressure targets and vasopressor titration are superior to fixed thresholds in surgical patients.